Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 02/24/2026 | Q4 | -- | -- | -- | -$0.51 | -- |
| 11/03/2025 | Q3 | -- | -- | -$0.59 | -$0.52 | -$0.07 |
| 08/05/2025 | Q2 | -- | -- | -$0.64 | -$0.58 | -$0.07 |
| 05/06/2025 | Q1 | -- | -- | -$0.52 | -$0.58 | $0.05 |
| 02/25/2025 | Q4 | -- | -- | -$0.61 | -$0.58 | -$0.03 |
| 11/12/2024 | Q3 | -- | -- | -$0.64 | -$0.57 | -$0.07 |
| 08/06/2024 | Q2 | -- | -- | -$0.59 | -$0.55 | -$0.04 |
| 05/07/2024 | Q1 | -- | -- | -$0.62 | -$0.51 | -$0.11 |
| 02/26/2024 | Q4 | -- | -- | -$0.63 | -$0.59 | -$0.04 |
| 11/02/2023 | Q3 | -- | -- | -$0.64 | -$0.53 | -$0.11 |
| 08/08/2023 | Q2 | -- | -- | -$0.59 | -$0.51 | -$0.08 |
| 05/09/2023 | Q1 | -- | -- | -$0.55 | -$0.54 | -$0.02 |
| 03/14/2023 | Q4 | -- | -- | -$0.56 | -$0.53 | -$0.03 |
| 11/14/2022 | Q3 | -- | -- | -$0.50 | -$0.52 | $0.02 |
| 08/09/2022 | Q2 | -- | -- | -$0.71 | -$0.68 | -$0.03 |
| 05/10/2022 | Q1 | -- | -- | -$0.68 | -$0.49 | -$0.19 |
| 03/15/2022 | Q4 | -- | -- | -$0.57 | -$0.48 | -$0.09 |
| 11/10/2021 | Q3 | -- | -- | -$0.48 | -$0.38 | -$0.10 |
| 08/16/2021 | Q2 | -- | -- | -$0.43 | -$0.35 | -$0.08 |
| 05/12/2021 | Q1 | -- | -- | -$0.34 | -$0.22 | -$0.12 |
| 03/26/2021 | Q4 | -- | -- | -$6.06 | -$0.68 | -$5.38 |
| 11/09/2020 | Q3 | -- | -- | -$5.07 | -$0.14 | -$4.93 |
| 08/11/2020 | Q2 | -- | -- | -$0.95 | -- | -- |
| 05/11/2020 | Q1 | -- | -- | -$0.81 | -- | -- |
| 03/26/2020 | Q4 | -- | -- | $0.28 | -- | -- |
| 11/12/2019 | Q3 | -- | -- | -$1.56 | -- | -- |
| 08/12/2019 | Q2 | -- | -- | -$1.36 | -- | -- |
| 05/13/2019 | Q1 | -- | -- | -$1.56 | -- | -- |
| 03/28/2019 | Q4 | -- | -- | -$1.08 | -- | -- |
| 11/12/2018 | Q3 | -- | -- | -$1.36 | -- | -- |
| 08/13/2018 | Q2 | -- | -- | -$1.24 | -- | -- |
| 03/31/2018 | Q1 | -- | -- | -$2.64 | -- | -- |
| 12/31/2017 | Q4 | -- | -- | -$0.91 | -- | -- |
| 09/30/2017 | Q3 | -- | -- | -$1.20 | -- | -- |
| 06/30/2017 | Q2 | -- | -- | -$1.00 | -- | -- |
| 03/31/2017 | Q1 | -- | -- | -$1.02 | -- | -- |
Cogent Biosciences, Inc. reported -- worth of top line sales in its most recent quarter.
Cogent Biosciences, Inc. announced earnings per share of -$0.59 which represents a miss of analyst forecast a -$0.52 per share.
Cogent Biosciences, Inc. reported -$1.1M that represents -$0.01 per share over the last quarter.
Cogent Biosciences, Inc.'s earnings are forecast to decrease from -$2.46 per share to -$2.40 per share next year representing a decrease of -8.79%.
Cogent Biosciences, Inc.'s next earnings date is February 24, 2026.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.